• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过放射受体分析法评估丙哌维林在异喹胍慢代谢者和快代谢者中的药代动力学。

Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine.

作者信息

Müller C, Siegmund W, Huupponen R, Kaila T, Franke G, Iisalo E, Zschiesche M

机构信息

University of Greifswald, Medical Faculty, Department of Clinical Pharmacology, Germany.

出版信息

Eur J Drug Metab Pharmacokinet. 1993 Jul-Sep;18(3):265-72. doi: 10.1007/BF03188807.

DOI:10.1007/BF03188807
PMID:8149945
Abstract

A pharmacokinetic study with 30 mg propiverine p.o. was performed in healthy volunteers (10 males, 6 females, age 36-56 years, body weight 55-100 kg, body height 162-184 cm, Broca index 0.96-1.19). 8 of them were poor and 8 extensive metabolizers of the debrisoquine type hydroxylation polymorphism. The total anticholinergic activity of the parent compound and active metabolites was measured with a radioreceptor assay calibrated with the metabolite M2. The affinity of this metabolite to the muscarinic receptors was similar to that of atropine. The urinary excretion of 3 major metabolites was determined with TLC and densitometry. Arterial blood pressure, heart rate, diameter of pupils, accommodation and parotic salivary flow were also measured. The concentrations of anticholinergic equivalents of propiverine were below 1 ng/ml of M2. 1.4-6.0% of the dose were excreted as N-oxidized metabolites into the urine. The poor and extensive metabolizers of debrisoquine did not differ significantly with regard to the concentration time behaviour of the active drug components, pattern of major metabolites, adverse drug reactions or any pharmacodynamic parameters measured.

摘要

在健康志愿者(10名男性,6名女性,年龄36 - 56岁,体重55 - 100 kg,身高162 - 184 cm,布罗卡指数0.96 - 1.19)中进行了一项口服30 mg丙哌维林的药代动力学研究。其中8人是异喹胍型羟基化多态性的慢代谢者,8人是快代谢者。用经代谢物M2校准的放射受体分析法测定母体化合物和活性代谢物的总抗胆碱能活性。该代谢物对毒蕈碱受体的亲和力与阿托品相似。用薄层色谱法和密度测定法测定3种主要代谢物的尿排泄量。还测量了动脉血压、心率、瞳孔直径、调节功能和腮腺唾液流量。丙哌维林的抗胆碱能等效物浓度低于1 ng/ml的M2。1.4 - 6.0%的剂量以N - 氧化代谢物的形式排泄到尿液中。异喹胍的慢代谢者和快代谢者在活性药物成分的浓度 - 时间行为、主要代谢物模式、药物不良反应或任何测量的药效学参数方面没有显著差异。

相似文献

1
Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine.通过放射受体分析法评估丙哌维林在异喹胍慢代谢者和快代谢者中的药代动力学。
Eur J Drug Metab Pharmacokinet. 1993 Jul-Sep;18(3):265-72. doi: 10.1007/BF03188807.
2
Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.药物氧化存在遗传缺陷的受试者的肝脏单加氧酶活性。
Gastroenterology. 1983 Sep;85(3):682-92.
3
Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.
Xenobiotica. 1989 Feb;19(2):225-30. doi: 10.3109/00498258909034695.
4
The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.西咪替丁对快代谢者中异喹胍4-羟化作用的影响。
Eur J Clin Pharmacol. 1989;36(3):319-21. doi: 10.1007/BF00558167.
5
Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.CYP2D6基因多态性对托特罗定药代动力学和药效学的影响。
Clin Pharmacol Ther. 1998 May;63(5):529-39. doi: 10.1016/S0009-9236(98)90104-7.
6
Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.
Acta Psychiatr Scand. 1993 Jan;87(1):23-8. doi: 10.1111/j.1600-0447.1993.tb03325.x.
7
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.异喹胍的药物遗传学及其作为CYP2D6羟化能力标志物的应用。
Pharmacogenomics. 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17.
8
[Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].[吉尔伯特-默伦格拉赫特综合征(GMS)中的基因多态性]
Z Gastroenterol. 1993 Feb;31 Suppl 2:81-2.
9
Debrisoquine hydroxylation in a Polish population.
Eur J Clin Pharmacol. 1995;47(6):503-5. doi: 10.1007/BF00193702.
10
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.3,4-脱氢去甲丙咪嗪,一种由4-羟基去甲丙咪嗪形成的新型去甲丙咪嗪代谢物,它会影响CYP2D6代谢率。
Drug Metab Dispos. 2006 Sep;34(9):1563-74. doi: 10.1124/dmd.105.008920. Epub 2006 Jun 16.

引用本文的文献

1
The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder.基因多态性对膀胱过度活动症患儿抗胆碱能治疗疗效的影响
Dis Markers. 2015;2015:732686. doi: 10.1155/2015/732686. Epub 2015 Jun 24.
2
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?用毒蕈碱受体拮抗剂治疗膀胱过度活动症:与代谢物有关?
Naunyn Schmiedebergs Arch Pharmacol. 2006 Nov;374(2):79-85. doi: 10.1007/s00210-006-0105-y.
3
Clinical pharmacokinetics of drugs used to treat urge incontinence.

本文引用的文献

1
The parotid and submandibular secretion in man. Quantitative recordings of the normal and pathological activity.
Acta Otolaryngol Suppl. 1962;172:1-67.
2
[Therapy of detrusor hyperactivity with propiverin (mictonorm)].
Z Urol Nephrol. 1981 Nov;74(11):827-32.
3
[Treatment of the symptoms of urinary urge and urge incontinence with propiverin hydrochloride (Mictonorm)].
Zentralbl Gynakol. 1984;106(14):981-7.
4
Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application.
Eur J Clin Pharmacol. 1984;26(5):613-7. doi: 10.1007/BF00543495.
用于治疗急迫性尿失禁药物的临床药代动力学
Clin Pharmacokinet. 2003;42(14):1243-85. doi: 10.2165/00003088-200342140-00004.
4
[Overactive bladder--treatment with antimuscarinic agents].[膀胱过度活动症——抗毒蕈碱药物治疗]
Urologe A. 2003 Jun;42(6):793-800. doi: 10.1007/s00120-003-0363-y. Epub 2003 May 20.
5
[Changes induced by Mictonorm in the urodynamics of the detrusor muscle in females with symptoms of the urge to urinate].
Z Urol Nephrol. 1985 Jul;78(7):363-70.
6
[Treatment of the unstable bladder in children with the anticholinergic agent propiverin hydrochloride (mictonorm/mictonets)].
Z Urol Nephrol. 1985 Mar;78(3):145-52.
7
[Personal experiences with conservative drug therapy of urgency symptoms in the female].
Z Urol Nephrol. 1986 Apr;79(4):197-205.
8
Gas chromatographic-mass fragmentographic determination of propiverine and its metabolites in plasma and urine.
J Chromatogr. 1987 Sep 4;420(1):43-52. doi: 10.1016/0378-4347(87)80153-6.
9
[The biotransformation of propiverin hydrochloride (Mictonorm)].
Pharmazie. 1988 Feb;43(2):96-8.
10
Studies on the metabolic pattern of propiverine in urine after single administration.
Pharmazie. 1988 Feb;43(2):91-5.